Assembly Biosciences (FRA:V7B) FCF Margin % : -200.59% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Assembly Biosciences's Free Cash Flow for the three months ended in Jun. 2024 was €-15.90 Mil. Assembly Biosciences's Revenue for the three months ended in Jun. 2024 was €7.93 Mil. Therefore, Assembly Biosciences's FCF Margin % for the quarter that ended in Jun. 2024 was -200.59%.

As of today, Assembly Biosciences's current FCF Yield % is 19.95%.

The historical rank and industry rank for Assembly Biosciences's FCF Margin % or its related term are showing as below:

FRA:V7B' s FCF Margin % Range Over the Past 10 Years
Min: -1542.88 Med: -261.74 Max: 313.95
Current: 109.75

During the past 13 years, the highest FCF Margin % of Assembly Biosciences was 313.95%. The lowest was -1542.88%. And the median was -261.74%.

FRA:V7B's FCF Margin % is ranked better than
97.9% of 1050 companies
in the Biotechnology industry
Industry Median: -143.325 vs FRA:V7B: 109.75

Assembly Biosciences FCF Margin % Historical Data

The historical data trend for Assembly Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences FCF Margin % Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-536.36

-82.39

-1,542.82

313.96

Assembly Biosciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial															-	-	1,028.23	-317.70	-200.59

Competitive Comparison of Assembly Biosciences's FCF Margin %

For the Biotechnology subindustry, Assembly Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's FCF Margin % falls into.

Assembly Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Assembly Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	20.621	/	6.568
	=	313.96 %

Assembly Biosciences's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-15.901	/	7.927
	=	-200.59 %

Assembly Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences Headlines

No Headlines